| תיאור כללי: |
The Prostate Cancer Research Program prioritizes research that will 1) develop better tools for early detection of clinically relevant disease, 2) distinguish aggressive from indolent disease in men newly diagnosed, 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer, and 4) develop strategies to optimize the physical and mental health of men with prostate cancer.
Health Disparity Research Award: Supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. New investigator option available. Qualified collaborator option supports a higher level of funding for PIs who include a collaborator that significantly contributes to the research. Nested Health Disparity Traineeship option supports predoctoral or postdoctoral training, nested within the overall proposed project. Funding: up to 400K-600K over up to 3 yrs.
Laboratory - Clinical Transition Award : Supports product-driven preclinical studies of promising novel lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care Robust preliminary data are required. Supports research ranging from preclinical study through current Good Manufacturing Practice Production. Collaboration with commercial partners is highly encouraged. Funding: up to $1.5M over up to 3 yrs.
Population Science Impact Award: Supports high-impact approaches to prostate cancer research from the perspective of population science studies, generating data and/or tools that can only be achieved from the perspective of systematic studies focused on specific populations of individuals. Studies should employ the logic, concepts, and methods of one or more population sciences: epidemiology, surveillance, health services research, outcomes research, behavioral science, social science, and dissemination research, among other areas. Topics may include, but are not limited to, biomarkers, genetics/ genomics; therapy and predictors of response or resistance; survivorship and palliative care; and health disparity. Funding: up to $750K over up to 4 yrs.
Clinical Exploration Award: Supports rapid execution of hypothesis-based, early phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II) to test interventions that will have a major impact on prostate cancer management. Also supports patient-based, innovative, hypothesis-driven correlative studies associated with existing/ongoing clinical trials. Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or others types. Funding: up to $450K over up to 5 yrs.
Prostate Cancer Biospecimen Resource Site Award: Provides support for infrastructure that will facilitate participation in an existing PCRP-funded prostate cancer biorepository network through the collection, processing, annotation, storage, and distribution of high-quality human biospecimens. Funding: up to $400K over up to 2 yrs
https://ebrap.org/eBRAP/public/Program.htm
|
